Johnson & Johnson Innovation Announces 17 Collaborations
Johnson & Johnson Innovation announces 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson Innovation to more than 200. The announcement includes the first alliance for the Disease Interception Accelerator (DIA), a research agreement with Washington University to identify the root cause of type 1 diabetes and enable the development of interventions that halt progression to disease.
"Johnson & Johnson Innovation is focused on bringing forward cutting-edge healthcare solutions that could extend and improve lives. The collaborations announced today aim to accelerate innovation at all stages of research and development," says Paul Stoffels, M.D., chief scientific officer, Johnson & Johnson and Worldwide chairman, Pharmaceuticals. "We are committed to working with researchers around the world to push the boundaries of what science and medicine can achieve to transform healthcare."
Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.
"Johnson & Johnson Innovation is focused on bringing forward cutting-edge healthcare solutions that could extend and improve lives. The collaborations announced today aim to accelerate innovation at all stages of research and development," says Paul Stoffels, M.D., chief scientific officer, Johnson & Johnson and Worldwide chairman, Pharmaceuticals. "We are committed to working with researchers around the world to push the boundaries of what science and medicine can achieve to transform healthcare."
Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.